Navigation Links
Scioderm to Present at 32nd Annual J.P. Morgan Healthcare Conference
Date:1/7/2014

DURHAM, N.C., Jan. 7, 2014 /PRNewswire/ -- Scioderm, Inc., today announced that Dr. Robert Ryan, President and Chief Executive Officer of Scioderm, was invited to present at the 32nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. Pacific Standard Time (10:30 a.m. EST) on Thursday, January 16, 2014 in the Elizabethan C/D room of the Westin St. Francis hotel.

Dr. Ryan will discuss the company's lead investigational therapy, SD-101, currently in late stage clinical development for the treatment of skin blistering and lesions associated with inherited Epidermolysis Bullosa, a rare orphan pediatric disease.   SD-101 for the treatment of EB has been granted orphan drug designation in the US and in December 2013 received a positive opinion by the Committee for Orphan Medicinal Products (COMP) in the EU. 

About Scioderm, Inc.

Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. The company is headquartered in Durham, North Carolina. In 2013, Scioderm, Inc. was the first biotech to receive "Breakthrough Therapy" designation for its lead product, SD-101, from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with Epidermolysis Bullosa. In addition, Scioderm was recently selected as  a 2013 "Fierce Top 15" company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry.  Additional information about Scioderm can be found at www.sderm.com

About SD-101

SD-101 is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. An open-label Phase II study was conducted previously in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB.  The primary outcome measurements were assessment of target wound reduction and closure, and reduction in body surface area (BSA) coverage of blisters and lesions.  In the clinical trial, SD-101 application resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in BSA coverage of blisters and lesions after 3 months of daily treatment.   SD-101 was well tolerated by the children, with daily administration up to 3 months.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks.  Actual results may differ materially from those projected.  These forward-looking statements represent our judgment as of the date of the release.  Scioderm disclaims any intent or obligation to update these forward-looking statements.

Investor and Media Contact

Robert Coull
Chief Operating Officer
robert.coull@sderm.com
(919)-824-2594


'/>"/>
SOURCE Scioderm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Scioderm, Inc. Named a 2013 "Fierce Top 15" Company by FierceBiotech
2. Scioderm Appoints Orphan Product Executives to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
7. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
8. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
11. PRA Expert to Present at Pharmacovigilance Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface and ... suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers real-world ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
(Date:1/18/2017)... N.J. , Jan. 18, 2017   Parent ... the fight to end Duchenne muscular dystrophy (Duchenne) ... to the New Jersey Institute of Technology (NJIT) and ... exploration of robotic technology to assist people ... to incorporate NJIT,s technology – an embedded computer, software, ...
(Date:1/18/2017)... Malden, MA (PRWEB) , ... January 18, 2017 ... ... announced today that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation ... Medical Center in Valley Stream, NY. The procedure was an anterior cervical discectomy ...
Breaking Biology Technology:
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... -- Onitor, provider of digital health technology for consumers, ... biometric data-driven program designed to aid weight loss for ... Consumer Electronics Show (CES) in Las Vegas ... World Health Organization (WHO), have identified lifestyle risks that ... overweight or obese. WHO also states that more people ...
(Date:12/22/2016)... 22, 2016 SuperCom (NASDAQ:   ... for the e-Government, Public Safety, HealthCare, and Finance sectors announced today ... been selected to implement and deploy a community-based supportive services program ... California , further expanding its presence in the state. ... This new program, which ...
Breaking Biology News(10 mins):